# A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer

> **NCT03822871** · PHASE1 · COMPLETED · sponsor: **Cancer Targeted Technology** · enrollment: 17 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** CTT1403
- **DRUG:** CTT1057
- **DRUG:** 68Ga-PSMA-11

## Key facts

- **NCT ID:** NCT03822871
- **Lead sponsor:** Cancer Targeted Technology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-01
- **Primary completion:** 2022-10-28
- **Final completion:** 2023-02-08
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-03-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03822871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03822871, "A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03822871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*